- Home
- HOTH vs NXTC Comparison
HOTH vs NXTC Comparison
Compare HOTH & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- NXTC
- Stock Information
- Founded
- HOTH 2017
- NXTC 2015
- Country
- HOTH United States
- NXTC United States
- Employees
- HOTH N/A
- NXTC N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- HOTH Health Care
- NXTC Health Care
- Exchange
- HOTH Nasdaq
- NXTC Nasdaq
- Market Cap
- HOTH 15.6M
- NXTC 12.8M
- IPO Year
- HOTH 2019
- NXTC 2019
- Fundamental
- Price
- HOTH $1.29
- NXTC $5.13
- Analyst Decision
- HOTH Strong Buy
- NXTC Strong Buy
- Analyst Count
- HOTH 3
- NXTC 2
- Target Price
- HOTH $4.00
- NXTC $25.50
- AVG Volume (30 Days)
- HOTH 230.9K
- NXTC 38.2K
- Earning Date
- HOTH 08-12-2025
- NXTC 08-07-2025
- Dividend Yield
- HOTH N/A
- NXTC N/A
- EPS Growth
- HOTH N/A
- NXTC N/A
- EPS
- HOTH N/A
- NXTC N/A
- Revenue
- HOTH N/A
- NXTC N/A
- Revenue This Year
- HOTH N/A
- NXTC N/A
- Revenue Next Year
- HOTH N/A
- NXTC N/A
- P/E Ratio
- HOTH N/A
- NXTC N/A
- Revenue Growth
- HOTH N/A
- NXTC N/A
- 52 Week Low
- HOTH $0.65
- NXTC $2.69
- 52 Week High
- HOTH $3.80
- NXTC $19.80
- Technical
- Relative Strength Index (RSI)
- HOTH 50.80
- NXTC 49.33
- Support Level
- HOTH $1.22
- NXTC $4.94
- Resistance Level
- HOTH $1.31
- NXTC $5.28
- Average True Range (ATR)
- HOTH 0.08
- NXTC 0.32
- MACD
- HOTH -0.00
- NXTC 0.03
- Stochastic Oscillator
- HOTH 57.69
- NXTC 43.18
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.